Description

TERIFRAC 750 MCG INJ 3ML

Indications

TERIFRAC 750 MCG INJ 3ML is primarily indicated for the treatment of iron deficiency anemia, particularly in patients who are unable to tolerate oral iron supplements or who have conditions that require rapid replenishment of iron stores. This injectable formulation is particularly beneficial for patients with chronic kidney disease, inflammatory bowel disease, or those undergoing hemodialysis. It is also indicated for patients with heavy menstrual bleeding or other conditions leading to significant blood loss.

Mechanism of Action

TERIFRAC contains ferric carboxymaltose, which is a complex of iron that is delivered intravenously. Upon administration, ferric carboxymaltose dissociates into ferric ions, which are then transported to the bone marrow for incorporation into hemoglobin. This process enhances erythropoiesis, leading to an increase in red blood cell production and subsequently improving hemoglobin levels. The unique formulation allows for high doses of iron to be administered safely in a short period, making it an effective option for rapid iron replenishment.

Pharmacological Properties

The pharmacokinetics of TERIFRAC involve rapid distribution of iron to tissues, with a half-life of approximately 7 hours post-infusion. The drug is primarily excreted via the reticuloendothelial system, with minimal renal excretion. The pharmacodynamic properties of TERIFRAC highlight its ability to effectively raise serum ferritin levels and hemoglobin concentration, thus addressing the symptoms of iron deficiency anemia. Clinical studies have demonstrated that patients receiving TERIFRAC show significant improvements in hemoglobin levels within a short treatment duration.

Contraindications

TERIFRAC is contraindicated in patients with known hypersensitivity to ferric carboxymaltose or any of its components. It should not be used in patients with iron overload syndromes, such as hemochromatosis or hemosiderosis, as excessive iron can lead to toxic effects. Additionally, it is contraindicated in patients with severe anemia of non-iron deficiency origin, where iron supplementation would not be beneficial.

Side Effects

Common side effects associated with TERIFRAC include mild to moderate reactions such as headache, dizziness, nausea, and injection site reactions (e.g., pain, swelling, or redness). More serious adverse effects, although rare, may include hypersensitivity reactions, anaphylaxis, and hypotension. It is essential for healthcare providers to monitor patients during and after administration for any signs of adverse reactions, particularly in the first dose.

Dosage and Administration

TERIFRAC is administered intravenously and should only be given by a qualified healthcare professional. The recommended dosage for adults is typically 750 mcg, which can be administered as a single dose or divided into multiple doses based on the patient’s needs and clinical response. The maximum cumulative dose should not exceed 1500 mcg within a week. For pediatric patients, dosing should be determined based on body weight and clinical assessment. It is crucial to follow the specific guidelines provided by healthcare authorities and adjust the dosage according to individual patient requirements.

Interactions

While TERIFRAC has a low potential for drug interactions, it is important to consider that concomitant use of other iron supplements may lead to iron overload. Additionally, medications that affect gastrointestinal motility or absorption may alter the efficacy of iron therapy. Healthcare providers should evaluate the patient’s complete medication profile to identify any potential interactions that may impact the effectiveness of TERIFRAC or increase the risk of adverse effects.

Precautions

Prior to administering TERIFRAC, it is essential to conduct a thorough medical history and physical examination to identify any contraindications or potential risks. Patients with a history of hypersensitivity to iron products should be monitored closely. Caution is advised in patients with a history of asthma or allergic conditions, as they may be at a higher risk for hypersensitivity reactions. Regular monitoring of hemoglobin levels and iron indices is recommended to assess the effectiveness of treatment and prevent iron overload. Pregnant and breastfeeding women should use TERIFRAC only if clearly needed and after careful consideration of the benefits versus risks.

Clinical Studies

Clinical studies evaluating the efficacy and safety of TERIFRAC have demonstrated its effectiveness in treating iron deficiency anemia. In a randomized controlled trial, patients receiving TERIFRAC showed a significant increase in hemoglobin levels compared to those receiving placebo. Another study highlighted the rapid increase in serum ferritin levels within weeks of treatment initiation, indicating effective iron replenishment. These studies support the use of TERIFRAC as a safe and effective option for managing iron deficiency anemia, particularly in patients who require rapid intervention.

Conclusion

TERIFRAC 750 MCG INJ 3ML is a valuable therapeutic option for patients suffering from iron deficiency anemia, especially those who cannot tolerate oral iron supplements. Its unique formulation allows for efficient iron delivery and rapid improvement in hemoglobin levels. However, careful patient selection, monitoring for side effects, and adherence to dosing guidelines are essential for optimizing treatment outcomes. As with any medication, healthcare providers should ensure that patients are fully informed about the benefits and risks associated with TERIFRAC therapy.